K Number
K982024
Device Name
OPIATES 2000 LIQUID OPIATES DRUGS OF ABUSE CONTROL LEVELS 2 AND 3
Date Cleared
1998-06-29

(20 days)

Product Code
Regulation Number
862.3280
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
Opiates 2000 Drugs of Abuse Controls are intended for use as a consistent test sample of known concentration for monitoring assay conditions in quantitative and qualitative analyses of patient urine specimens. Include the controls with patient urine specimens when assaying for opiates.
Device Description
Not Found
More Information

Not Found

Not Found

No
The summary describes a control solution for drug testing, which is a chemical reagent, not a software or hardware device that would typically incorporate AI/ML. There are no mentions of AI, ML, image processing, or any other indicators of AI/ML technology.

No
The device is described as "Opiates 2000 Drugs of Abuse Controls" and its intended use is "as a consistent test sample of known concentration for monitoring assay conditions...Include the controls with patient urine specimens when assaying for opiates." This indicates it is a quality control product for laboratory drug testing, not a device used to treat a disease or condition.

No
The device is described as "controls" for monitoring assay conditions, implying it's a quality control material used to verify the performance of a diagnostic test, rather than a diagnostic device itself that directly diagnoses a patient.

No

The 510(k) summary describes "Opiates 2000 Drugs of Abuse Controls," which are intended for use as test samples in urine analysis. This description strongly suggests a physical control material, not a software-only device. The lack of any mention of software, algorithms, or digital processing further supports this conclusion.

Based on the provided information, this device is an IVD (In Vitro Diagnostic).

Here's why:

  • Intended Use: The intended use explicitly states that the controls are for "monitoring assay conditions in quantitative and qualitative analyses of patient urine specimens." This indicates that the device is used in vitro (outside the body) to analyze a human specimen (urine) for diagnostic purposes (monitoring assay conditions related to drug testing).
  • Specimen Type: The device is used with "patient urine specimens," which is a human biological sample.
  • Purpose: The purpose is to ensure the accuracy and consistency of drug testing assays, which are diagnostic procedures.

While the description is brief and lacks details about the device itself, the intended use clearly aligns with the definition of an In Vitro Diagnostic device.

N/A

Intended Use / Indications for Use

Opiates 2000 Drugs of Abuse Controls are intended for use as a consistent test sample of known concentration for monitoring assay conditions in quantitative and qualitative analyses of patient urine specimens. Include the controls with patient urine specimens when assaying for opiates.

Product codes

DIF

Device Description

Not Found

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies

Not Found

Key Metrics

Not Found

Predicate Device(s)

Not Found

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 862.3280 Clinical toxicology control material.

(a)
Identification. A clinical toxicology control material is a device intended to provide an estimation of the precision of a device test system and to detect and monitor systematic deviations from accuracy resulting from reagent or instrument defects. This generic type of device includes various single, and multi-analyte control materials.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.

0

Image /page/0/Picture/2 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo features a stylized eagle with three stripes representing the department's services. The words "HUMAN SERVICES • USA" are arranged in an arc above the eagle, and the words "DEPARTMENT OF HEALTH" are arranged in an arc below the eagle. The logo is black and white.

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

JUN 2 9 1998

Scot D. Kinghorn Director, Quality and Regulatory Affairs Medical Analysis Systems, Inc. Lincoln Technology Park 542 Flynn Road Camarillo, California 93012-8058

Re : K982024 Opiates 2000 Liquid Opiates Drugs of Abuse Control Levels 2 and 3 Regulatory Class: I Product Code: DIF Dated: June 5, 1998 Received: June 9, 1998

Dear Mr. Kinghorn:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions The general controls provisions of the Act of the Act. include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Requlations, Title 21, Parts 800 to 895. ಗ್ substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory In addition, FDA may publish further announcements action. concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or requlations.

1

Page 2

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to
premarket notification" (21 CFR 807.97). Other gener Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "dsmo@fdadr.cdrh.fda.gov".

Sincerely yours,

Steven Autman

Steven I. Gutman, M.D., M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

2

MEDICAL ANALYSIS SYSTEMS, INC.

510(k) Number: K982024 Device Name: Opiates 2000 Liquid Opiates Drugs of Abuse Control Levels 2 and 3

STATEMENT OF INDICATIONS FOR USE

Opiates 2000 Drugs of Abuse Controls are intended for use as a consistent test sample of known concentration for monitoring assay conditions in quantitative and qualitative analyses of patient urine specimens. Include the controls with patient urine specimens when assaying for opiates.

Carol C. Benson / Alfred Montgomery

(Division Sign-Off)
Division of Clinical Laboratory Devices
510(k) Number K982024

\Prescription Use

Image /page/2/Picture/9 description: The image contains two logos. The logo on the left has text in a box. The logo on the right has a triangle inside of a circle.